INTRODUCTION: Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD). METHODS: Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods. RESULTS: Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised ~ 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity. CONCLUSIONS: Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.

• MeSH
• antibiotická profylaxe MeSH
• dospělí MeSH
• infekční komplikace v těhotenství * epidemiologie   mikrobiologie   MeSH
• lidé MeSH
• mladý dospělý MeSH
• novorozenec MeSH
• přenašečství epidemiologie   mikrobiologie   MeSH
• Streptococcus agalactiae * izolace a purifikace   klasifikace   MeSH
• streptokokové infekce * epidemiologie   mikrobiologie   prevence a kontrola   MeSH
• těhotenství MeSH
• vagina mikrobiologie   MeSH
• vertikální přenos infekce statistika a číselné údaje   prevence a kontrola   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mladý dospělý MeSH
• novorozenec MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• Geografické názvy
• Evropa MeSH

Asthma bronchiale je jedno z nejčastějších chronických onemocnění vyskytující se v průběhu těhotenství, které může významně komplikovat a nepříznivě ovlivňovat kvalitu života matky. U těhotných astmatiček stoupá riziko rozvoje preeklampsie, předčasného porodu a porodu dítěte s nízkou porodní hmotností. Většina komplikací souvisí s nedostatečnou kontrolou onemocnění u pacientek, jejichž astma není správně léčeno, nebo si samy vysazují doporučenou medikaci. Průběh astmatu během těhotenství je nepředvídatelný, u mnoha žen se tíže astmatu mění a exacerbace přicházejí nejčastěji v průběhu druhého trimestru. Léčebným cílem je zajistit těhotné pacientce s astmatem jak optimální léčbu k udržení kontroly astmatu, tak podmínky pro normální fetální vývoj. Tento článek poskytuje na základě dostupné literatury aktuální informace o diagnóze, monitorování onemocnění a systematické léčbě astmatu v těhotenství.

Bronchial asthma is one of the most common chronic diseases occurring during pregnancy, which can significantly complicate and negatively impact the mother‘s quality of life. Pregnant women with asthma have an increased risk of developing preeclampsia, preterm labor and delivering a baby with low birth weight. Most complications are connected to poor control of the disease in patients whose asthma is not well managed or who discontinue their prescribed medication. The course of asthma during pregnancy is unpredictable, with many women experiencing changes in severity and exacerbations most commonly occurring during the second trimester. The treatment goal is to provide pregnant patients with optimal asthma management to maintain control of the disease while ensuring conditions for normal fetal development. This article provides current information based on available literature regarding the diagnosis, moni- toring, and systematic treatment of bronchial asthma during pregnancy.

Cíl: Těhotenství se nepovažuje za stav zvyšující náchylnost organismu k infekci SARS-CoV-2 (severe-acute-respiratory-syndrome-related coronavirus 2), avšak v případě nákazy v graviditě se zvyšuje riziko závažnějšího průběhu nemoci covid-19. Ve většině případů ovšem bývá průběh infekce v graviditě mírný nebo bezpříznakový. Hlavním cílem studie u těhotných žen s covidem-19 (coronavirové onemocnění) bylo dokázat, že způsob porodu se nemění a závažné komplikace jak porodnické, tak neonatologické se kvůli tomuto onemocnění nevyskytují častěji. Metody: Do retrospektivní, observační, multicentrické studie byly zařazeny pacientky s pozitivním testem na covid-19, které byly přijaty a následně porodily v období od 15. března 2020 do 15. března 2021. Data z porodnických oddělení pěti center v České republice během pandemie covidu-19 byla analyzována ve vztahu k metodě a době porodu, symptomům covidu-19 a potenciálním komplikacím s ohledem na demografii a komorbidity těhotných žen. Infekce koronavirem byla u pacientek potvrzena pomocí PCR (polymerázové řetězové reakce). Statistická analýza byla hodnocena pomocí programu Excel. Výsledky: Během sledovaného období bylo ve studijních centrech detekováno 236 těhotných žen s covidem-19. Většina pacientek byla asymptomatická (59,7 %). U symptomatických pacientek byly nejčastějšími příznaky kašel (52,6 %), nachlazení (43,2 %) a horečka (37,9 %) a covidová pneumonie byla diagnostikována u 8 pacientek. Porod byl proveden vaginálně u 52,5 % pacientek, těhotenství bylo ukončeno císařským řezem v 44,5 %, per VEX (vakuumextrakce) v 2,1 % a per forcipem v 0,8 % případů. Průměrný týden gravidity v době porodu byl 38 a předčasný porod byl proveden u 19,1 % pacientek. Výsledky tyto studie u těhotných žen s covidem-19 prokázaly, že způsob porodu se nezměnil a výskyt větších komplikací jak porodnických, tak neonatologických nebyl ve většině případů zaznamenán. Dva prezentované závažné průběhy covidu-19 u těhotných žen však vedly k předčasnému ukončení těhotenství. Jediným přidruženým rizikovým faktorem byla obezita pacientky. Závěry: Ačkoli je covid-19 onemocnění, které je u těhotných žen většinou asymptomatické nebo má pouze mírné příznaky podobné chřipce, je spojeno se zvýšenou nemocností a úmrtností ve srovnání s těhotnými ženami bez covidu-19. Výzvou do budoucna je možnost segregace pacientek do nízko a vysoce rizikových skupin na základě prokázaných rizikových faktorů a důsledné očkování těhotných žen nebo žen plánujících početí. V kritických případech je nutné správné načasování předčasného ukončení těhotenství a včasná indikace počátku zrání plic plodu.

Objective: Pregnancy is not considered a condition that increases the body‘s susceptibility to SARS-CoV-2 (severe-acute-respiratory-syndrome-related coronavirus-2) infection, but in the case of infection in pregnancy, there is an increased risk of a more severe course of COVID-19 (coronavirus disease-19). However, the course of infection in pregnancy is mild or asymptomatic in most cases. The main objective of the study in pregnant women with COVID-19 was to prove that the delivery method is not changed, and serious complications do not occur more frequently due to this disease. Methods: In a retrospective, observational, multicentric study, the pregnant women positively tested to COVID-19 were admitted and subsequently gave birth in the period from 15 March 2020 to 15 March 2021. Data from the delivery departments of five centers in the Czech Republic during COVID-19 pandemic were analyzed in relation to the delivery method and time, COVID-19 symptoms and potential complications with respect to demographics and comorbidities of pregnant women. COVID-19 positivity was confirmed with PCR (polymerase-chain reaction). The Excel program was used during statistical analysis. Results: During the observed study period, 236 pregnant women with COVID-19 were detected at study centers. Most of the patients were asymptomatic (59.7%). In symptomatic patients, most common symptoms were cough (52.6 %), cold (43.2%) and fever (37.9%), and COVID-19 pneumonia was diagnosed in 8 patients. The delivery was performed vaginally in 52.5% patients, the pregnancy was terminated by C-section (cesarean section) in 44.5%, per VEX (vacuum extractor) in 2.1% and per forcipem in 0.8% cases. The average week of pregnancy at the time of delivery was 38 (29–41) and preterm delivery was performed in 19.1% patients. The study results in pregnant women with COVID-19 demonstrated that the method of delivery was not changed and major delivery and neonatological complications did not develop in most cases. However, two presented serious courses of COVID-19 in pregnant women led to premature terminations of pregnancies. The only associated risk factor was the patient‘s obesity. Conclusions: Although COVID-19 is a disease that is mostly asymptomatic in pregnant women or with only mild flu-like symptoms, it is associated with increased morbidity and mortality compared to pregnant women without COVID-19. The challenge for the future is the possibility of segregating patients into lowand high-risk groups based on proven risk factors, and consistent vaccination of pregnant women or women planning conception. In critical cases, the correct timing of premature termination of pregnancy and early indication of the beginning of fetal lung maturation is necessary.

• MeSH
• COVID-19 * komplikace   mortalita   MeSH
• diagnostické zobrazování metody   MeSH
• komplikace porodu * mikrobiologie   MeSH
• komplikace těhotenství * mikrobiologie   MeSH
• lidé MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• Check Tag
• lidé MeSH
• Geografické názvy
• Česká republika MeSH

INTRODUCTION AND OBJECTIVES: Limited information is available on the safety of pregnancy in patients with genetic dilated cardiomyopathy (DCM) and in carriers of DCM-causing genetic variants without the DCM phenotype. We assessed cardiac, obstetric, and fetal or neonatal outcomes in this group of patients. METHODS: We studied 48 women carrying pathogenic or likely pathogenic DCM-associated variants (30 with DCM and 18 without DCM) who had 83 pregnancies. Adverse cardiac events were defined as heart failure (HF), sustained ventricular tachycardia, ventricular assist device implantation, heart transplant, and/or maternal cardiac death during pregnancy, or labor and delivery, and up to the sixth postpartum month. RESULTS: A total of 15 patients, all with DCM (31% of the total cohort and 50% of women with DCM) experienced adverse cardiac events. Obstetric and fetal or neonatal complications were observed in 14% of pregnancies (10 in DCM patients and 2 in genetic carriers). We analyzed the 30 women who had been evaluated before their first pregnancy (12 with overt DCM and 18 without the phenotype). Five of the 12 (42%) women with DCM had adverse cardiac events despite showing NYHA class I or II before pregnancy. Most of these women had a history of cardiac events before pregnancy (80%). Among the 18 women without phenotype, 3 (17%) developed DCM toward the end of pregnancy. CONCLUSIONS: Cardiac complications during pregnancy and postpartum were common in patients with genetic DCM and were primarily related to HF. Despite apparently good tolerance of pregnancy in unaffected genetic carriers, pregnancy may act as a trigger for DCM onset in a subset of these women.

• MeSH
• dilatační kardiomyopatie * genetika   komplikace   MeSH
• dospělí MeSH
• fenotyp MeSH
• genetická variace MeSH
• kardiovaskulární komplikace v těhotenství * genetika   MeSH
• lidé MeSH
• těhotenství MeSH
• výsledek těhotenství * MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Heteropágy alebo parazitické zrastené dvojčatá predstavujú extrémne zriedkavú anomáliu, ktorá sa vyskytuje približne v 1 z 1 milióna prípadov. Sú charakterizované prítomnosťou parazitického dvojčaťa s významnou vrodenou abnormalitou, pripojeného k zvyčajne inak zdravému plodu. Dobre vyvinuté dvojča je známe ako „autosite“ alebo „hostiteľ“, zatiaľ čo ťažko postihnutý plod sa nazýva „parazit“. Prežitie defektného dvojčaťa závisí od kardiovaskulárneho systému druhého, relatívne normálneho plodu. Predstavujeme prípad 27-ročnej primigravidy v 14. týždni gravidity s ultrazvukovým nálezom poukazujúcim na parazitické zrastené dvojčatá, omfalopágy.

Heteropagus or parasitic conjoined twins represent an extremely rare anomaly, occurring in approximately 1 in 1 million cases. This condition is characterized by the presence of a parasitic twin with significant congenital abnormalities attached to an otherwise typically healthy fetus. The well-developed twin is known as the “autosite” or “host,” while the severely affected fetus is termed the “parasite.” Survival of the defective twin depends on the cardiovascular system of the second, relatively normal fetus. We present the case of a 27-year-old primigravida in her 14th week of pregnancy with ultrasound findings indicating parasitic conjoined twins, specifically omphalopagus.

• MeSH
• dospělí MeSH
• fetus in fetu * diagnóza   MeSH
• komplikace těhotenství MeSH
• lidé MeSH
• monstra duplicia * MeSH
• prenatální diagnóza MeSH
• těhotenství MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

OBJECTIVE: Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia within 4 weeks of sampling. METHODS: Multinational European prospective observational pilot study of predominantly high-risk patients in the second half of pregnancy to assess a point-of-care immunoassay for GlyFn in predicting preeclampsia within 4 weeks of sampling. GlyFn was measured using a second generation hand held POC immunoassay. Results were considered normal for GlyFn concentrations of < 350 μg/mL, positive for GlyFn concentrations of 351-600 μg/mL, and high-positive for GlyFn concentrations > 600 μg/mL. RESULTS: Preeclampsia developed in 16 (19%) of 84 subjects and was associated with a shorter gestational age at delivery 35.3 weeks vs. 37.3 weeks for non-preeclamptics, n = 82; p = 0.001), a higher risk of fetal growth restriction (FGR; 31.2% vs. 10.3% for non-preeclamptics, p = 0.046), and an increased risk of preterm birth < 37 weeks gestation (83.3% vs. 33.3% for non-preeclamptics, (n = 78; p = 0.003). GlyFn positive or high positive was seen in 13/16 (81%) and in 35/68 (51.5%), yielding a sensitivity of 81%, a specificity of 49%, a positive predictive value of 27%, and a negative predictive value of 92%. GlyFn positive or high positive was also associated with preterm birth < 37 weeks in singleton pregnancy non-preeclamptic patients. Preterm birth occurred in 4.8% of those with normal GlyFn, in 26.7% with positive GlyFn, and in 50% of those with high GlyFn in singleton gestations without preeclampsia (p = 0.008). CONCLUSION: The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.

• MeSH
• biologické markery analýza   MeSH
• dospělí MeSH
• fibronektiny * analýza   MeSH
• gestační stáří MeSH
• glykované proteiny MeSH
• imunoanalýza metody   MeSH
• lidé MeSH
• pilotní projekty MeSH
• point of care testing MeSH
• prediktivní hodnota testů MeSH
• preeklampsie * diagnóza   MeSH
• prospektivní studie MeSH
• těhotenství MeSH
• vyšetření u lůžka MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• pozorovací studie MeSH

OBJECTIVES: To analyze the prevalence and severity of fetal aortic regurgitation (AR) after undergoing successful fetal aortic valvuloplasty (FAV) and to evaluate its effects on fetal circulation and left ventricular (LV) growth. METHODS: This was a retrospective review of all fetuses with critical aortic stenosis who underwent successful FAV at our center between 2010 and 2024 for whom postnatal echocardiograms were available in digital format. Fetal and postnatal echocardiographic examinations were analyzed for ventricular and valvular dimensions and characteristics, and Z-scores were calculated for middle cerebral artery (MCA) pulsatility index (PI), umbilical artery (UA) PI and cerebroplacental ratio. AR severity was classified into no/mild AR or significant (moderate/severe) AR. The balloon-to-aortic valve ratio (BVR) was calculated as the ratio between the maximum actual balloon diameter and the aortic valve (AV) annulus diameter. The primary endpoints of this study were the prevalence, severity and risk factors for fetal AR following successful FAV. RESULTS: Ninety-nine fetuses who underwent successful FAV were included. Immediate post-FAV echocardiograms showed that 87% of fetuses developed some degree of AR, including 45% of all fetuses with significant AR. BVR was significantly higher in fetuses with significant AR compared to those with no/mild AR (mean, 1.09 (95% CI, 1.06-1.12) vs 1.02 (95% CI, 0.99-1.04); P < 0.001). In a subgroup of 66/99 fetuses with available postnatal echocardiograms, the prevalence of AR decreased significantly from 86% before birth to 58% after birth (P < 0.001), with the proportion of fetuses with significant AR reducing from 47% before birth to 17% after birth (P < 0.001). In the overall cohort of fetuses, AV maximum velocity (Vmax) increased significantly from post-FAV to after birth (mean, 1.93 (95% CI, 1.75-2.11) m/s vs 3.21 (95% CI, 2.89-3.55) m/s; P < 0.001), regardless of AR severity, but Vmax after birth was lower in the significant-AR group compared with the no/mild-AR group (mean, 2.85 m/s vs 3.55 m/s; P = 0.020). Fetuses with significant AR exhibited higher relative LV length increases from immediately post-FAV to after birth than did those with no/mild AR (25% (95% CI, 16-33%) vs 14% (95% CI, 6-21%); P = 0.044), although there was no significant difference in mean LV length Z-score after birth between the two groups. FAV led to significant short-term increases in MCA-PI and UA-PI Z-scores, with greater increases observed in fetuses with significant AR. CONCLUSIONS: FAV is associated with a high prevalence of fetal AR, which lessens in severity over the course of gestation. Significant fetal AR had the largest association with greater BVR and had significant impact on fetal hemodynamics. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

• MeSH
• aortální chlopeň diagnostické zobrazování   embryologie   MeSH
• aortální insuficience * diagnostické zobrazování   epidemiologie   patofyziologie   MeSH
• aortální stenóza diagnostické zobrazování   embryologie   epidemiologie   patofyziologie   MeSH
• balónková valvuloplastika * MeSH
• dospělí MeSH
• echokardiografie metody   MeSH
• fetální srdce diagnostické zobrazování   patofyziologie   MeSH
• gestační stáří MeSH
• lidé MeSH
• nemoci plodu epidemiologie   diagnostické zobrazování   MeSH
• novorozenec MeSH
• prevalence MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• stupeň závažnosti nemoci MeSH
• těhotenství MeSH
• ultrasonografie prenatální * MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• novorozenec MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: The rapid increase in cannabis use during pregnancy-up by 170 % between 2009 and 2016-raises pressing concerns about its effects on fetal health, particularly on the delicate monoamine system within the fetoplacental unit, which is crucial for placental function and neurodevelopment. OBJECTIVE: This systematic review explores the impact of prenatal cannabinoid exposure on the monoamine system within the fetoplacental unit, with a focus on its implications for fetal development through the lens of the Developmental Origins of Health and Disease (DOHaD) framework. METHODS: A comprehensive search across multiple databases initially retrieved 18,252 papers. After rigorous screening, only 16 animal studies and 4 human studies met the inclusion criteria. Findings were synthesized to evaluate the effects of prenatal cannabis exposure on neurotransmitter regulation, receptor function, and gene expression. RESULTS: Although no studies directly addressed the monoamine system in the placenta, animal models revealed significant disruptions in neurotransmitter regulation and neurodevelopmental changes following prenatal cannabis exposure. Human studies suggested potential cognitive and behavioral risks for offspring exposed in utero. CONCLUSION: This review exposes a critical gap in the literature on cannabis' effects on the placental monoamine system. While evidence points to notable neurodevelopmental risks, the scarcity of focused research underscores the need for further investigation to fully understand the implications of prenatal cannabis exposure.

• MeSH
• biogenní monoaminy metabolismus   MeSH
• kanabinoidy * metabolismus   MeSH
• lidé MeSH
• placenta * metabolismus   účinky léků   MeSH
• těhotenství MeSH
• vývoj plodu účinky léků   MeSH
• zpožděný efekt prenatální expozice * metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• systematický přehled MeSH

INTRODUCTION: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile. AREAS COVERED: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024. Our search using the global Espacenet database identified numerous compounds with low nanomolar inhibitory concentrations against FLT3-ITD and FLT3-TKD mutants. These compounds have shown promise in preclinical studies. Co-inhibition strategies and combinatorial therapies to overcome resistance and enhance anti-leukemic efficacy are also discussed. EXPERT OPINION: Recent patents highlight advances in the field of FLT3 inhibitors with a focus on overcoming resistance, improving selectivity and potency. Future strategies may include third-generation inhibitors such as type III allosteric inhibitors, irreversible inhibitors, or PROTACs. Personalized medicine approaches utilizing genetic profiling to tailor therapies are emphasized. Exploration of novel combination regimens with emerging therapies like CAR T-cell therapy, immune checkpoint inhibitors, and small molecules targeting critical AML pathways is ongoing to further enhance anti-leukemic efficacy.

• MeSH
• akutní myeloidní leukemie * farmakoterapie   genetika   MeSH
• chemorezistence * MeSH
• individualizovaná medicína MeSH
• inhibitory proteinkinas * farmakologie   MeSH
• lidé MeSH
• mutace * MeSH
• patenty jako téma * MeSH
• prognóza MeSH
• protinádorové látky * farmakologie   MeSH
• staurosporin analogy a deriváty   farmakologie   MeSH
• tyrosinkinasa 3 podobná fms * antagonisté a inhibitory   genetika   MeSH
• vyvíjení léků MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Gestational diabetes mellitus (GDM) is a common complication of pregnancy in which women without previously diagnosed diabetes develop chronic hyperglycemia during pregnancy. It is associated with a number of maternal and fetal/neonatal complications. The role of the adipokines retinol binding protein-4, resistin and nesfatin-1 in the development of GDM is relatively poorly understood, but their role in glucose metabolism is suspected and their use as early markers to predict the development of GDM is being sought. The aim of study was to determine the correlation between the levels of selected adipokines (retinol binding protein-4, resistin, nesfatin-1) in women with gestational diabetes mellitus (GDM) and healthy pregnant women and to compare their levels with other clinical and biochemical parameters. Patients with GDM had significantly higher BMI (28.4±4.5 vs. 24.6±4 kg/m2), total cholesterol (6±1.3 vs. 5.3±1.4 mmol/l) and triacylglycerols (1.9±0.8 vs. 1.4±0.7 mmol/l) than women in the control group. RBP4 confirms the significant difference between the groups, it is higher in the control group of healthy pregnant women. The adipokines resistin and nesfatin-1 show no differences between the control and GDM groups, but their ratios with BMI, cholesterol and triacylglycerols, resistin shows elevated levels in the control group. In women with GDM, RBP4 was significantly positively correlated with C-peptide and negatively correlated with total, LDL, and non-HDL cholesterol. Resistin was also negatively correlated with total, LDL, HDL, and non-HDL cholesterol. Nesfatin-1 was only moderately positively correlated with glycated hemoglobin (HbA1C) and fasting glycemia. There is ambiguity in the results of previous studies on the levels of the investigated adipokines in pregnant women with GDM and the interpretation depends on many factors. Keywords: Gestational diabetes, Adipokines, Retinol-binding protein 4, Resistin, Nesfatin-1.

• MeSH
• adipokiny krev   MeSH
• biologické markery * krev   MeSH
• DNA vazebné proteiny krev   MeSH
• dospělí MeSH
• gestační diabetes * krev   diagnóza   MeSH
• krevní glukóza metabolismus   MeSH
• lidé MeSH
• nukleobindiny * krev   MeSH
• plazmatické proteiny vázající retinol * metabolismus   analýza   MeSH
• proteiny nervové tkáně krev   MeSH
• proteiny vázající vápník krev   MeSH
• resistin * krev   MeSH
• studie případů a kontrol MeSH
• těhotenství MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH